We are live on ! Find out more
MIRA icon

MIRA Pharmaceuticals

26 hedge funds and large institutions have $2.19M invested in MIRA Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.38% more ownership

Funds ownership: 5.13%5.51% (+0.38%)

0% more funds holding

Funds holding: 2626 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

5% less capital invested

Capital invested by funds: $2.3M → $2.19M (-$106K)

Holders
26
Holders Change
Holders Change %
0%
% of All Funds
0.31%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
6
Reduced
6
Closed
4
Calls
Puts
Net Calls
Net Calls Change

MIRA Hedge Fund Activity: Q2 2026 in Review

26 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in MIRA Pharmaceuticals (MIRA) for Q2 2026, worth a combined $2.19M — down 4.6% from $2.3M a quarter earlier.

Fund positioning in MIRA was balanced in Q2 2026: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 6 trimmed.

The largest buyer was BlackRock, adding an estimated $134K. The largest seller was Suncoast Equity Management, exiting entirely with an estimated $97K sold.

  • 26 institutional investors held MIRA Pharmaceuticals (MIRA) as of Q2 2026, unchanged from Q1 2026.
  • Funds reported $2.19M of MIRA Pharmaceuticals stock for Q2 2026, down 4.6% quarter-over-quarter.
  • 4 funds opened new MIRA Pharmaceuticals positions in Q2 2026 and 4 closed out, a net change of 0 holders.
  • The largest MIRA Pharmaceuticals buyer in Q2 2026 was BlackRock, an estimated $134K added.
  • The largest MIRA Pharmaceuticals seller in Q2 2026 was Suncoast Equity Management, an estimated $97K sold.

Based on aggregated 13F filings for Q2 2026.